Pure Financial Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.36M | Buy |
20,029
+1,999
| +11% | +$443K | 0.06% | 120 |
|
|
2025
Q4 | $4.12M | Buy |
18,030
+7,705
| +75% | +$1.76M | 0.06% | 118 |
|
|
2025
Q3 | $2.39M | Buy |
10,325
+761
| +8% | +$155K | 0.04% | 148 |
|
|
2025
Q2 | $1.78M | Buy |
9,564
+2,035
| +27% | +$378K | 0.03% | 162 |
|
|
2025
Q1 | $1.58M | Buy |
7,529
+149
| +2% | +$29K | 0.03% | 139 |
|
|
2024
Q4 | $1.31M | Buy |
7,380
+389
| +6% | +$71.5K | 0.03% | 148 |
|
|
2024
Q3 | $1.38M | Sell |
6,991
-11,103
| -61% | -$2.07M | 0.03% | 135 |
|
|
2024
Q2 | $3.1M | Sell |
18,094
-493
| -3% | -$81.7K | 0.09% | 95 |
|
|
2024
Q1 | $3.38M | Buy |
18,587
+219
| +1% | +$37.7K | 0.11% | 91 |
|
|
2023
Q4 | $2.85M | Buy |
18,368
+233
| +1% | +$34K | 0.1% | 91 |
|
|
2023
Q3 | $2.7M | Buy |
18,135
+416
| +2% | +$61.1K | 0.11% | 83 |
|
|
2023
Q2 | $2.39M | Buy |
17,719
+426
| +2% | +$62.5K | 0.1% | 89 |
|
|
2023
Q1 | $2.76M | Buy |
17,293
+1,146
| +7% | +$175K | 0.13% | 81 |
|
|
2022
Q4 | $2.61M | Sell |
16,147
-228
| -1% | -$35K | 0.13% | 75 |
|
|
2022
Q3 | $2.2M | Sell |
16,375
-1,615
| -9% | -$232K | 0.13% | 81 |
|
|
2022
Q2 | $2.75M | Buy |
17,990
+334
| +2% | +$51K | 0.17% | 73 |
|
|
2022
Q1 | $2.86M | Buy |
17,656
+129
| +0.7% | +$18.7K | 0.13% | 74 |
|
|
2021
Q4 | $2.37M | Buy |
17,527
+290
| +2% | +$34.3K | 0.12% | 73 |
|
|
2021
Q3 | $1.86M | Buy |
17,237
+311
| +2% | +$35.5K | 0.14% | 72 |
|
|
2021
Q2 | $1.91M | Sell |
16,926
-107
| -0.6% | -$12.1K | 0.16% | 70 |
|
|
2021
Q1 | $1.84M | Buy |
17,033
+125
| +0.7% | +$13.4K | 0.18% | 68 |
|
|
2020
Q4 | $1.81M | Buy |
16,908
+30
| +0.2% | +$2.88K | 0.22% | 67 |
|
|
2020
Q3 | $1.48M | Buy |
16,878
+637
| +4% | +$60K | 0.22% | 66 |
|
|
2020
Q2 | $1.59M | Buy |
16,241
+4,101
| +34% | +$361K | 0.25% | 56 |
|
|
2020
Q1 | $925K | Sell |
12,140
-33
| -0.3% | -$2.81K | 0.16% | 69 |
|
|
2019
Q4 | $1.08M | Buy |
12,173
+327
| +3% | +$27.1K | 0.18% | 65 |
|
|
2019
Q3 | $897K | Buy |
11,846
+142
| +1% | +$9.73K | 0.16% | 69 |
|
|
2019
Q2 | $851K | Sell |
11,704
-74
| -0.6% | -$5.82K | 0.15% | 70 |
|
|
2019
Q1 | $949K | Buy |
11,778
+172
| +1% | +$14.1K | 0.18% | 64 |
|
|
2018
Q4 | $1.07M | Buy |
11,606
+116
| +1% | +$10.2K | 0.22% | 56 |
|
|
2018
Q3 | $1.09M | Buy |
+11,490
| New | +$1.09M | 0.24% | 55 |
|
|
2017
Q4 | – | Sell |
-11,204
| Closed | -$996K | – | 4 |
|
|
2017
Q3 | $996K | Buy |
11,204
+96
| +0.9% | +$7.31K | 0.26% | 44 |
|
|
2017
Q2 | $805K | Buy |
11,108
+358
| +3% | +$24.1K | 0.22% | 47 |
|
|
2017
Q1 | $700K | Buy |
10,750
+104
| +1% | +$6.54K | 0.2% | 52 |
|
|
2016
Q4 | $667K | Buy |
10,646
+24
| +0.2% | +$1.47K | 0.2% | 51 |
|
|
2016
Q3 | $670K | Buy |
10,622
+76
| +0.7% | +$4.92K | 0.22% | 48 |
|
|
2016
Q2 | $653K | Buy |
10,546
+132
| +1% | +$8.04K | 0.22% | 41 |
|
|
2016
Q1 | $598K | Buy |
10,414
+105
| +1% | +$5.85K | 0.21% | 47 |
|
|
2015
Q4 | $611K | Buy |
10,309
+209
| +2% | +$12K | 0.26% | 34 |
|
|
2015
Q3 | $550K | Hold |
10,100
| – | – | 0.26% | 33 |
|
|
2015
Q2 | $679K | Buy |
+10,100
| New | +$659K | 0.34% | 30 |
|
Other funds holding ABBV
VCM
VPM
Pure Financial Advisors's ABBV Position: Q1 2026 in Review
Pure Financial Advisors increased its AbbVie (ABBV) stake by 11% in Q1 2026, buying an estimated $443K and bringing the position to 20,029 shares worth $4.36M. The position accounts for 0.06% of the portfolio, ranked #120.
Pure Financial Advisors first reported a position in ABBV in Q2 2015 and has held it in 41 quarters since. 4,087 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Pure Financial Advisors held 20,029 shares of AbbVie worth $4.36M as of Q1 2026.
- Pure Financial Advisors bought 1,999 AbbVie shares in Q1 2026, an estimated $443K.
- AbbVie made up 0.06% of Pure Financial Advisors's portfolio in Q1 2026, its #120 holding.
- Pure Financial Advisors first reported a position in AbbVie in Q2 2015 and has held it in 41 quarters since.
- 4,087 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Pure Financial Advisors's 13F filing for Q1 2026, filed 10 Apr 2026.